The clinical trials data related to the vaccination of the CNBG's inactivated COVID-19 doses in high-risk groups in China showed that the vaccine offers strong immunogenicity and safety to the elderly, can effectively prevent severe illness and death, and is safe in combined inoculation with influenza and pneumonia vaccines, the Global Times learned exclusively from the China National Biotec Group (CNBG) under Chinese state-owned Sinopharm on Saturday.